within Pharmacolibrary.Drugs.ATC.A;

model A11CC55
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.6,
    Cl             = 0.00025,
    adminDuration  = 600,
    adminMass      = 1.0,
    adminCount     = 1,
    Vd             = 0.0005,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0002666666666666667,
    Tlag           = 600
  );

  annotation(Documentation(
    info ="<html><body><p>Colecalciferol (vitamin D3), often used in combination with other vitamins and minerals, is a fat-soluble vitamin primarily used for the prevention and treatment of vitamin D deficiency, rickets, and certain bone disorders. Combinations may be indicated in cases where multiple nutrient deficiencies are addressed. It is an approved and commonly used medication and supplement globally.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters estimated for a typical healthy adult population, as no direct clinical PK publications for colecalciferol combinations could be identified.</p><h4>References</h4><ol><li><p>Reynolds, NA, &amp; Curran, MP (2005). Alendronate/colecalciferol. <i>Treatments in endocrinology</i> 4(6) 371–379. DOI:<a href=&quot;https://doi.org/10.2165/00024677-200504060-00006&quot;>10.2165/00024677-200504060-00006</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/16318403/&quot;>https://pubmed.ncbi.nlm.nih.gov/16318403</a></p></li><li><p>Levine, BS, &amp; Song, M (1996). Pharmacokinetics and efficacy of pulse oral versus intravenous calcitriol in hemodialysis patients. <i>Journal of the American Society of Nephrology : JASN</i> 7(3) 488–496. DOI:<a href=&quot;https://doi.org/10.1681/ASN.V73488&quot;>10.1681/ASN.V73488</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/8704116/&quot;>https://pubmed.ncbi.nlm.nih.gov/8704116</a></p></li><li><p>Muindi, JR, et al., &amp; Trump, DL (2002). Pharmacokinetics of high-dose oral calcitriol: results from a phase 1 trial of calcitriol and paclitaxel. <i>Clinical pharmacology and therapeutics</i> 72(6) 648–659. DOI:<a href=&quot;https://doi.org/10.1067/mcp.2002.129305&quot;>10.1067/mcp.2002.129305</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/12496746/&quot;>https://pubmed.ncbi.nlm.nih.gov/12496746</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end A11CC55;
